Literature DB >> 24900726

Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor.

David C Fry1, Charles Wartchow1, Bradford Graves1, Cheryl Janson1, Christine Lukacs1, Ursula Kammlott1, Charles Belunis1, Stefan Palme2, Christian Klein3, Binh Vu1.   

Abstract

Protein-protein interaction (PPI) systems represent a rich potential source of targets for drug discovery, but historically have proven to be difficult, particularly in the lead identification stage. Application of the fragment-based approach may help toward success with this target class. To provide an example toward understanding the potential issues associated with such an application, we have deconstructed one of the best established protein-protein inhibitors, the Nutlin series that inhibits the interaction between MDM2 and p53, into fragments, and surveyed the resulting binding properties using heteronuclear single quantum coherence nuclear magnetic resonance (HSQC NMR), surface plasmon resonance (SPR), and X-ray crystallography. We report the relative contributions toward binding affinity for each of the key substituents of the Nutlin molecule and show that this series could hypothetically have been discovered via a fragment approach. We find that the smallest fragment of Nutlin that retains binding accesses two subpockets of MDM2 and has a molecular weight at the high end of the range that normally defines fragments.

Entities:  

Keywords:  MDM2; Nutlin; binding affinity; p53; protein−protein interaction inhibitor

Year:  2013        PMID: 24900726      PMCID: PMC4027557          DOI: 10.1021/ml400062c

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  15 in total

1.  Ligand efficiency: a useful metric for lead selection.

Authors:  Andrew L Hopkins; Colin R Groom; Alexander Alex
Journal:  Drug Discov Today       Date:  2004-05-15       Impact factor: 7.851

Review 2.  Fragment-based approaches in drug discovery and chemical biology.

Authors:  Duncan E Scott; Anthony G Coyne; Sean A Hudson; Chris Abell
Journal:  Biochemistry       Date:  2012-06-14       Impact factor: 3.162

Review 3.  Using fragment-based technologies to target protein-protein interactions.

Authors:  Justin F Bower; Andrew Pannifer
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 4.  Using chemical shift perturbation to characterise ligand binding.

Authors:  Mike P Williamson
Journal:  Prog Nucl Magn Reson Spectrosc       Date:  2013-03-21       Impact factor: 9.795

5.  Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.

Authors:  P H Kussie; S Gorina; V Marechal; B Elenbaas; J Moreau; A J Levine; N P Pavletich
Journal:  Science       Date:  1996-11-08       Impact factor: 47.728

6.  Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides.

Authors:  S M Picksley; B Vojtesek; A Sparks; D P Lane
Journal:  Oncogene       Date:  1994-09       Impact factor: 9.867

7.  Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.

Authors:  Binh Vu; Peter Wovkulich; Giacomo Pizzolato; Allen Lovey; Qingjie Ding; Nan Jiang; Jin-Jun Liu; Chunlin Zhao; Kelli Glenn; Yang Wen; Christian Tovar; Kathryn Packman; Lyubomir Vassilev; Bradford Graves
Journal:  ACS Med Chem Lett       Date:  2013-04-02       Impact factor: 4.345

8.  Fragment-based deconstruction of Bcl-xL inhibitors.

Authors:  Sarah Barelier; Julien Pons; Olivier Marcillat; Jean-Marc Lancelin; Isabelle Krimm
Journal:  J Med Chem       Date:  2010-03-25       Impact factor: 7.446

Review 9.  Rationalizing the chemical space of protein-protein interaction inhibitors.

Authors:  Olivier Sperandio; Christelle H Reynès; Anne-Claude Camproux; Bruno O Villoutreix
Journal:  Drug Discov Today       Date:  2009-12-05       Impact factor: 7.851

10.  In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Authors:  Lyubomir T Vassilev; Binh T Vu; Bradford Graves; Daisy Carvajal; Frank Podlaski; Zoran Filipovic; Norman Kong; Ursula Kammlott; Christine Lukacs; Christian Klein; Nader Fotouhi; Emily A Liu
Journal:  Science       Date:  2004-01-02       Impact factor: 47.728

View more
  20 in total

1.  Extending the Detection Limit in Fragment Screening of Proteins Using Reverse Micelle Encapsulation.

Authors:  Brian Fuglestad; Nicole E Kerstetter; Sabrina Bédard; A Joshua Wand
Journal:  ACS Chem Biol       Date:  2019-10-03       Impact factor: 5.100

2.  Ligand deconstruction: Why some fragment binding positions are conserved and others are not.

Authors:  Dima Kozakov; David R Hall; Stefan Jehle; Sefan Jehle; Lingqi Luo; Stefan O Ochiana; Elizabeth V Jones; Michael Pollastri; Karen N Allen; Adrian Whitty; Sandor Vajda
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

Review 3.  Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases.

Authors:  Vladimir N Uversky; Vrushank Davé; Lilia M Iakoucheva; Prerna Malaney; Steven J Metallo; Ravi Ramesh Pathak; Andreas C Joerger
Journal:  Chem Rev       Date:  2014-05-15       Impact factor: 60.622

Review 4.  Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.

Authors:  Duncan E Scott; Andrew R Bayly; Chris Abell; John Skidmore
Journal:  Nat Rev Drug Discov       Date:  2016-04-11       Impact factor: 84.694

5.  When Does Chemical Elaboration Induce a Ligand To Change Its Binding Mode?

Authors:  Shipra Malhotra; John Karanicolas
Journal:  J Med Chem       Date:  2016-12-16       Impact factor: 7.446

6.  Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein-protein interaction.

Authors:  Maxim Gureev; Daria Novikova; Tatyana Grigoreva; Svetlana Vorona; Alexander Garabadzhiu; Vyacheslav Tribulovich
Journal:  J Comput Aided Mol Des       Date:  2019-11-28       Impact factor: 3.686

7.  Activity-Directed Synthesis of Inhibitors of the p53/hDM2 Protein-Protein Interaction.

Authors:  Adam I Green; Fruzsina Hobor; Christopher P Tinworth; Stuart Warriner; Andrew J Wilson; Adam Nelson
Journal:  Chemistry       Date:  2020-08-04       Impact factor: 5.236

Review 8.  Lessons from Hot Spot Analysis for Fragment-Based Drug Discovery.

Authors:  David R Hall; Dima Kozakov; Adrian Whitty; Sandor Vajda
Journal:  Trends Pharmacol Sci       Date:  2015-11-01       Impact factor: 14.819

9.  Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.

Authors:  Michael Andreeff; Kevin R Kelly; Karen Yee; Sarit Assouline; Roger Strair; Leslie Popplewell; David Bowen; Giovanni Martinelli; Mark W Drummond; Paresh Vyas; Mark Kirschbaum; Swaminathan Padmanabhan Iyer; Vivian Ruvolo; Graciela M Nogueras González; Xuelin Huang; Gong Chen; Bradford Graves; Steven Blotner; Peter Bridge; Lori Jukofsky; Steve Middleton; Monica Reckner; Ruediger Rueger; Jianguo Zhi; Gwen Nichols; Kensuke Kojima
Journal:  Clin Cancer Res       Date:  2015-10-12       Impact factor: 12.531

10.  Query-guided protein-protein interaction inhibitor discovery.

Authors:  Sergio Celis; Fruzsina Hobor; Thomas James; Gail J Bartlett; Amaurys A Ibarra; Deborah K Shoemark; Zsófia Hegedüs; Kristina Hetherington; Derek N Woolfson; Richard B Sessions; Thomas A Edwards; David M Andrews; Adam Nelson; Andrew J Wilson
Journal:  Chem Sci       Date:  2021-03-02       Impact factor: 9.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.